A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission.
Publication
, Conference
Gray, HJ; Secord, AA; Anderson, ML; DelPriore, G; Tchabo, NE; Berek, JS
Published in: Journal of Clinical Oncology
May 20, 2010
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15_suppl
Start / End Page
TPS171 / TPS171
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Gray, H. J., Secord, A. A., Anderson, M. L., DelPriore, G., Tchabo, N. E., & Berek, J. S. (2010). A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission. In Journal of Clinical Oncology (Vol. 28, pp. TPS171–TPS171). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2010.28.15_suppl.tps171
Gray, H. J., A. A. Secord, M. L. Anderson, G. DelPriore, N. E. Tchabo, and J. S. Berek. “A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission.” In Journal of Clinical Oncology, 28:TPS171–TPS171. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.tps171.
Gray HJ, Secord AA, Anderson ML, DelPriore G, Tchabo NE, Berek JS. A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. TPS171–TPS171.
Gray, H. J., et al. “A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission.” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2010, pp. TPS171–TPS171. Crossref, doi:10.1200/jco.2010.28.15_suppl.tps171.
Gray HJ, Secord AA, Anderson ML, DelPriore G, Tchabo NE, Berek JS. A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. TPS171–TPS171.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15_suppl
Start / End Page
TPS171 / TPS171
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences